Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T ; volume:14 ; number:1 ; day:12 ; month:4 ; year:2024 ; pages:1-2 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (12.4.2024), 1-2, 12.2024
- Urheber
-
Richter, Joshua
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01049-z
- URN
-
urn:nbn:de:101:1-2406252107148.411513601753
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 05.11.2025, 15:52 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Richter, Joshua
- SpringerLink (Online service)
Ähnliche Objekte (12)
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study